Astellas: fails to get injunction vs FDA over Prograf

TOKYO Aug 13 (Reuters) - Japan's Astellas Pharma (4503.T) said on Thursday a U.S. court has rejected its request for an injunction to prevent the Food and Drug Administration from approving generic products to its top-selling Prograf transplant drug.

Astellas, Japan's No.2 drugmaker, filed a complaint against the FDA, after the U.S. drug regulators knocked back its request for higher hurdles for generic rivals to Prograf. [ID:nT344249]

Swiss drugmaker Novartis (NOVN.VX) launched the first generic version of Prograf on Tuesday, sending Astellas shares 8 percent lower over the last two days.

The stock was up 0.8 percent at 3,600 yen in early trade on Thursday.

Astellas said in a statement it is evaluating its next course of action. (Reporting by Yumiko Nishitani; Editing by Edwina Gibbs)